OK first off - I am relatively new to Opthea although I have watched them for many years. I was hoping one of the old hands could explain the reasons for the high market cap to me. My understanding - and I could be completely wrong here - is that OPT-302 has now been in two phase II trials in combination with other agents. In both trials the addition of OPT-302 did not markedly (and in the case of the recent trial not significantly) improve the outcome for patients. Why would consumers pay for an additional agent with a marginal if any benefit, and more importantly why would a third party pharmaceutical company pay good money for such an asset. I can't see too much in the pipeline behind OPT-302 so I'm wondering if the emperor has new clothes so to speak. In other words what is the basis for the very significant market capitalization. I honestly can't see why we should fund a phase III in any of these indications and any secondary endpoint yet to be disclosed are unlikely to change the value proposition.
SJ
- Forums
- ASX - By Stock
- OPT
- explain the market cap
explain the market cap
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $321.4M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 49.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.0¢ | 7766 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.495 |
1 | 10000 | 0.490 |
1 | 1100 | 0.480 |
1 | 6000 | 0.470 |
3 | 57022 | 0.460 |
Price($) | Vol. | No. |
---|---|---|
0.440 | 7766 | 1 |
0.445 | 78554 | 1 |
0.485 | 10221 | 1 |
0.495 | 1290 | 1 |
0.500 | 13237 | 1 |
Last trade - 16.14pm 07/06/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
Day chart unavailable